Biochemical and immunological status following gene therapy and PEG-ADA therapy for adenosine deaminase (ADA) deficiency.
暂无分享，去创建一个
H. Simmonds | V. V. van Beusechem | H. Gaspar | L. Fairbanks | R. Levinsky | D. Valerio | A. Moseley | G. Morgan | P. Hoogerbrugge
[1] W. Anderson,et al. Treatment of Severe Combined Immunodeficiency Disease (SCID) due to Adenosine Deaminase Deficiency with CD34+ Selected Autologous Peripheral Blood Cells Transduced with a Human ADA Gene (Amendment). National Institutes of Health , 1993 .
[2] G. MacGregor,et al. Renal artery stenosis and prediction of risk of vascular surgery , 1993, The Lancet.
[3] J. Hughes,et al. Adult presentation of adenosine deaminase deficiency , 1993, The Lancet.
[4] M. Hershfield,et al. Enzyme Replacement Therapy with Polyethylene Glycol-Adenosine Deaminase in Adenosine Deaminase Deficiency: Overview and Case Reports of Three Patients, Including Two Now Receiving Gene Therapy , 1993, Pediatric Research.
[5] D. Valerio,et al. Long-term expression of human adenosine deaminase in rhesus monkeys transplanted with retrovirus-infected bone-marrow cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[6] H. Simmonds,et al. Heterogeneity of biochemical, clinical and immunological parameters in severe combined immunodeficiency due to adenosine deaminase deficiency. , 1987, Clinical and experimental immunology.
[7] H. Simmonds,et al. Human B lymphocytes and thymocytes but not peripheral blood mononuclear cells accumulate high dATP levels in conditions simulating ADA deficiency. , 1985, Biochemical pharmacology.